Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

The pharmacokinetics and pharmacodynamics of atenolol and timolol were studied in six extensive and four poor metabolisers of debrisoquine. There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and the area under the plasma concentration time curve (AUC) for timolol (rs = 0.75, P less than 0.02). The mean of the AUC values for timolol was significantly greater in the poor metabolisers than in the extensive metabolisers (P less than 0.05). There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and beta-adrenoceptor blockade 24 h after dosing with timolol (rs = 0.66, P less than 0.05). The mean degree of beta-adrenoceptor blockade was significantly greater in the poor metabolisers than in the extensive metabolisers 24 h after dosing with timolol (P less than 0.01). There was no relation between the debrisoquine to 4-hydroxydebrisoquine ratio and the pharmacokinetics or pharmacodynamics of atenolol.

[1]  M. Lennard,et al.  Timolol determination in plasma and urine by high-performance liquid chromatography with ultraviolet detection. , 1985, Journal of chromatography.

[2]  D. Roden,et al.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man. , 1984, The Journal of pharmacology and experimental therapeutics.

[3]  G. Tucker,et al.  Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.

[4]  P. Vlasses,et al.  Relationships among timolol doses, plasma concentrations and beta-adrenoceptor blocking activity. , 1982, British journal of clinical pharmacology.

[5]  L. Ramsay,et al.  Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. , 1982, British journal of clinical pharmacology.

[6]  G. Alván,et al.  HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION , 1982, The Lancet.

[7]  O. Hensens,et al.  Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities. , 1980, Journal of medicinal chemistry.

[8]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[9]  J. Idle,et al.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  T. Blaschke,et al.  Atenolol determination by high-performance liquid chromatography and fluorescence detection. , 1979, Journal of chromatography.

[11]  J. Idle,et al.  Polymorphism of carbon oxidation of drugs and clinical implications. , 1978, British medical journal.

[12]  D. Tocco,et al.  Physiological disposition and metabolism of timolol in man and laboratory animals. , 1975, Drug metabolism and disposition: the biological fate of chemicals.